Market Place
Sourcing Support
Ivonescimab Ph3 Data In NSCLC To Be Featured At ELCC 2026
27 Mar 2026 //
BUSINESSWIRE
FDA Accepts BLA for Ivonescimab Combo in NSCLC Post-TKI Therapy
30 Jan 2026 //
PRESS RELEASE
Summit Pharma`s Ivonescimab (BLA) Accepted By FDA For EGFRm NSCLC
29 Jan 2026 //
BUSINESSWIRE
Ivonescimab HARMONi-A Final OS Data Presented With HR=0.74
07 Nov 2025 //
PR NEWSWIRE
HARMONi-A OS Data for Ivonescimab in EGFRm NSCLC at SITC 2025
31 Oct 2025 //
BUSINESSWIRE
Summit Therapeutics Raises $500 Million In Private Placement
22 Oct 2025 //
BUSINESS WIRE
Summit Targets 2025 FDA Application For Ivonescimab Post
21 Oct 2025 //
BIOSPACE
Akeso, Summit PD-1/VEGF Blocker Exceeds Survival Expectations
20 Oct 2025 //
BIOSPACE
Summit Pharma Updates Q3 Financials And Operational Progress
20 Oct 2025 //
BUSINESSWIRE
Akeso, Summit`s Ivonescimab Beats PD-1 In Chemo Combo In 1L NSCLC
19 Oct 2025 //
FIERCE BIOTECH
Summit Expands Ivonescimab Phase III To Include Harmoni-Gi3 Study
17 Oct 2025 //
BUSINESSWIRE
HARMONi-6 Ivonescimab + Chemo Vs Tislelizumab In 1L NSCLC At ESMO
24 Sep 2025 //
BUSINESSWIRE
Summit`s Keytruda Rival Faces US Approval Hurdles Due to Issues
08 Sep 2025 //
BIOSPACE
Ph 3 HarmonI Trial: Ivonescimab Plus Chemo Improves Survival
07 Sep 2025 //
BUSINESSWIRE
Ivonescimab Ph 3 HARMONi Data to Be Presented at WCLC 2025
14 Aug 2025 //
BUSINESSWIRE
Summit stock drops on Akeso bispecific OS data vs. Keytruda
25 Apr 2025 //
FIERCE PHARMA
Summit’s Beats Yet Another Cancer Med, Pressuring Keytruda
24 Apr 2025 //
BIOSPACE
Akeso Highlights Summit Therapeutics and Pfizer Collaboration
24 Feb 2025 //
PR NEWSWIRE
Merck signs up to $3.3 billion cancer drug deal with LaNova
16 Nov 2024 //
REUTERS
Summit Completes HARMONi Trial Enrollment For NSCLC Treatment
03 Oct 2024 //
BUSINESSWIRE
Ivonescimab Combo Shows Promise In CRC, TNBC, HNSCC at ESMO 2024
16 Sep 2024 //
BUSINESSWIRE
Summit Therapeutics Raises $235 Million
12 Sep 2024 //
BUSINESSWIRE
Akeso, Summit`s PD-1 Bispecific Outperforms Keytruda In Lung Cancer
09 Sep 2024 //
FIERCE PHARMA
Ivonescimab Outperforms Pembrolizumab In First-Line PD-L1+ NSCLC
08 Sep 2024 //
BUSINESSWIRE
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
03 Jun 2024 //
BUSINESSWIRE
Ivonescimab HARMONi-A Trial Manuscript Published In JAMA
01 Jun 2024 //
BUSINESSWIRE
Ivonescimab-Chemo Combo Approved In China For EGFRm NSCLC After Chemo
01 Jun 2024 //
BUSINESSWIRE
Summit Cancer Study Triumph Over Keytruda In China
30 May 2024 //
ENDPTS
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC
14 Mar 2024 //
BUSINESSWIRE
Summit Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
16 Oct 2023 //
BUSINESSWIRE
Promising Data for Innovative Bispecific Ivonescimab Featured at ASCO 2023
04 Jun 2023 //
BUSINESSWIRE
Ivonescimab Updated Data to be Featured at ASCO 2023
01 Jun 2023 //
BUSINESSWIRE
Summit Announces Initial Indications for Trials for Ivonescimab (SMT112)
03 May 2023 //
BUSINESSWIRE
Summit Closes Deal with Akeso to In-License Innovative Bispecific Antibody
20 Jan 2023 //
BUSINESSWIRE
